Last reviewed · How we verify
NCT07378358
Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study
trial testing Large Language Model Assessment (ChatGPT, Gemini, DeepSeek) in Urologic Diseases in 800 participants. Currently enrolling.
1 April 2026
Quick facts
| Lead sponsor | First Affiliated Hospital of Fujian Medical University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 800 |
| Start date | 1 January 2026 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Large Language Model Assessment (ChatGPT, Gemini, DeepSeek)
Conditions studied
- Urologic Diseases — all drugs for Urologic Diseases →
Sponsor
First Affiliated Hospital of Fujian Medical University
Who can join
18 and older, any sex, with Urologic Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This multicenter retrospective study aims to evaluate the diagnostic and therapeutic performance of three large language models-ChatGPT, Gemini and Deepseek-using 800 archived inpatient medical records from urology departments across four tertiary hospitals. The study will focus on the accuracy and applicability of these models in disease recognition, preliminary diagnosis and treatment recommendation generation, in order to explore their potential value and limitations in supporting clinical decision-making in real-world settings.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07378358
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urologic Diseases
Currently open trials in the same condition.
- NCT07338292 — VIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures · NA · recruiting
- NCT06676527 — Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma · recruiting
- NCT06531473 — Laser Outcomes Associated With (Holmium Laser Enucleation of the Prostate) HoLEP Procedures · NA · recruiting
- NCT07395037 — A Study of Ward Admissions for Haematuria · recruiting
- NCT06397287 — PROM Project Urology · recruiting
Other First Affiliated Hospital of Fujian Medical University trials
Trials by the same sponsor.
- NCT07513844 — Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease · NA · not yet recruiting
- NCT07337772 — Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty · NA · recruiting
- NCT07369401 — Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory · NA · not yet recruiting
- NCT07363382 — The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer · Phase 1, PHASE2 · recruiting
- NCT07313215 — Rifampin-combined Antibiotic Therapy for Staphylococcal PJI · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07378358 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Fujian Medical University
- Last refreshed: 30 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07378358.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing